-
公开(公告)号：US20250067754A1
公开(公告)日：2025-02-27
申请号：US18735006
申请日：2024-06-05
Applicant: BRAINBOX SOLUTIONS, INC.
Inventor： RACHEL SOREK , KEREN JAKOBI , DONNA EDMONDS
IPC: G01N33/68 , C07K14/47 , G01N33/543 , G01N33/96
Abstract: Methods and compositions for diagnosing brain injury, neurodegeneration; or a predisposition thereto, in a subject are provided. Particularly, the present invention relates to specific antigen antibody reactivities useful in diagnosing brain injury, neurodegeneration or a predisposition thereto, in a subject.
-
公开(公告)号：US20250066486A1
公开(公告)日：2025-02-27
申请号：US18825514
申请日：2024-09-05
Applicant: Orionis Biosciences Inc. , Orionis Biosciences BV
Inventor： Nikolai KLEY , Jan TAVERNIER , Lennart ZABEAU , Erik DEPLA
IPC: C07K16/28 , A61K38/17 , A61K38/21 , A61K39/395 , A61K39/40 , A61K39/42 , A61P25/00 , C07K14/47 , C07K16/00 , C07K16/18
Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
-
公开(公告)号：US20250066436A1
公开(公告)日：2025-02-27
申请号：US18723022
申请日：2022-12-20
Applicant: ROYAL COLLEGE OF SURGEONS IN IRELAND
Inventor： Roger PRESTON , Orla WILLIS FOX
IPC: C07K14/47 , A61K38/00 , A61P7/02 , C07K14/445
Abstract: A conjugate comprising a P. falciparum erythrocyte membrane protein 1 (PfEMP1) CIDRα1.4 domain fused to a therapeutic agent.
-
公开(公告)号：US20250059243A1
公开(公告)日：2025-02-20
申请号：US18756596
申请日：2024-06-27
Applicant: TRUSTEES OF BOSTON UNIVERSITY
Inventor： Ahmad S. KHALIL , Kok Ann GAN , Hanrong YE , Thea Samuelle ORNSTEIN
Abstract: The technology described herein is directed to regulated synthetic gene expression systems. In one aspect described herein are synthetic transcription factors (synTFs) comprising a DNA binding domain, a transcriptional activator domain, a transcriptional effector domain (TED), and optionally a regulator protein. In other aspects described herein are gene expression systems comprising said synTFs and methods of treating diseases and disorders using said synTFs.
-
公开(公告)号：US20250057982A1
公开(公告)日：2025-02-20
申请号：US18827357
申请日：2024-09-06
Inventor： Mauro Giacca , Giulia Ruozi , Francesca Bortolotti
Abstract: A protein selected from the group consisting of Chrdl1, Fam3c, Fam3b and a fragment thereof, or a polynucleotide encoding therefor, for use in treating or reducing the risk of heart disease.
-
Patent Agency Ranking
公开(公告)号：US12228579B2
公开(公告)日：2025-02-18
申请号：US17841704
申请日：2022-06-16
Applicant: MeMed Diagnostics Ltd.
Inventor： Eran Eden , Kfir Oved , Assaf Cohen-Dotan , Roy Navon , Olga Boico , Meital Paz
IPC: G01N33/50 , G01N33/52 , G01N33/53 , G01N33/58 , G01N33/60 , G01N33/68 , G16H50/20 , G16H50/30 , G16H50/70 , C07K14/47 , C07K14/52 , C07K14/525 , C07K14/54
Abstract: A method of determining a management course for treating a subject showing symptoms of a disease is disclosed. The method comprises measuring the TRAIL protein level in a blood sample of the subject, wherein when the TRAIL level is below a predetermined amount, the subject is treated as a high-risk patient.
-
公开(公告)号：US12227588B2
公开(公告)日：2025-02-18
申请号：US18620748
申请日：2024-03-28
Inventor： Marco Ruella , Saar Gill , Carl H. June , Avery D. Posey , Daniel J. Powell
IPC: C07K16/28 , A61K35/17 , A61K38/00 , A61K39/00 , A61P35/00 , A61P35/02 , C07K14/47 , C07K14/705 , C07K14/725 , C12N5/0783
Abstract: The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.
-
公开(公告)号：US20250051410A1
公开(公告)日：2025-02-13
申请号：US18722601
申请日：2022-12-22
Applicant: KAHR Medical Ltd.
Inventor： Ami TAMIR , Itai BLOCH
IPC: C07K14/47 , A61K38/00 , A61P37/04 , C07K14/705
Abstract: LILRB polypeptides are provided. Accordingly, there is provided a LILRB polypeptide capable of binding an HLA-G polypeptide as set forth in SEQ ID NO: 3 and having at least one mutation located within amino acid positions 40-60 of a D1 domain of LILRB, wherein the LILRB polypeptide has an increased stability and/or increased affinity to HLA-G compared to a LILRB polypeptide of the same length and sequence not comprising the at least one mutation. Also provided are polynucleotides encoding the LILRB polypeptide, host cells expressing the LILRB polypeptide and methods of producing and using same.
-
公开(公告)号：US20250051407A1
公开(公告)日：2025-02-13
申请号：US18799107
申请日：2024-08-09
Applicant: University of Washington
Inventor： David Baker , Cameron Glasscock , Robert Pecoraro , Ryan McHugh , Christoffer Norn , Frank DiMaio , David Benjamin Turitz Cox , Brian Coventry , Hugh Haddox , Gyu Rie Lee
Abstract: Polypeptides are provided that include an amino acid sequence at least 50% identical, not including any amino acid insertions at identified insertion sites, to the amino acid sequence selected from the group consisting of SEQ ID NO: 1-52, wherein the polypeptide is a sequence-specific DNA-binding polypeptide, fusion proteins comprising such polypeptides, nucleic acids encoding such polypeptides and fusion proteins, and expression vectors and host cells comprising such nucleic acids.
-
公开(公告)号：US20250049917A1
公开(公告)日：2025-02-13
申请号：US18719622
申请日：2022-12-14
Applicant: KINGS COLLEGE LONDON
Inventor： Sophie PAPA , Robert PAGE , Esperanza PERUCHA
Abstract: An immune cell that is genetically engineered to express an exogenous alternative carbon source (ACS) metabolism gene, in which the ACS is not glucose and wherein the ability of the immune cell to metabolise the ACS is increased due to expression of the exogenous ACS metabolism gene. Also provided are polynucleotides, vectors, pharmaceutical compositions, methods of genetically engineering the immune cell and methods of use in therapy.
-
-
-
-
-
-
-
-
-
Search Results
19419
records
(took 0.065 seconds)
